Skip to main content

Table 4 Impact of study characteristics to the effects of atorvastatin therapy on serum adiponectin concentrations: results of subgroup analyses

From: Effect of atorvastatin treatment on circulating adiponectin: a meta-analysis of randomized controlled trials

Study characteristics

WMD of serum adiponectin concentration (ug/ml)

Comparisons (patients), n

I2

WMD [95% CI]

p1

p2

R, DB, PC studies

 Yes

4 (396)

73%

− 1.02 [−2.27, 0.22]

0.11

 

 No

10 (535)

50%

0.06 [−0.64, 0.77]

0.86

0.14

Crossover studies

 Yes

2 (196)

0%

−0.13 [− 0.72, 0.46]

0.66

 

 No

12 (735)

65%

−0.33 [−1.13, 0.47]

0.42

0.70

Patients with DM

 Yes

5 (396)

59%

−0.95 [−2.18, 0.29]

0.13

 

 No

9 (535)

57%

0.03 [−0.65, 0.71]

0.96

0.18

Patients with dyslipidemia

 Yes

7 (398)

0%

−0.28 [−0.75, 0.19]

0.24

 

 No

7 (533)

79%

−0.42 [−1.71, 0.87]

0.52

0.84

Mean age

 ≤ 56 years

7 (419)

80%

0.02 [−1.13, 1.18]

0.97

 

 > 56 years

7 (512)

0%

−0.54 [−1.13, 0.04]

0.07

0.39

Male

 ≤ 52%

8 (499)

56%

0.09 [−0.63, 0.81]

0.81

 

 > 52%

6 (432)

65%

−0.88 [−2.02, 0.27]

0.13

0.16

BMI

 ≤ 26 kg/m2

9 (535)

57%

0.03 [−0.65, 0.71]

0.94

 

 > 26 kg/m2

5 (396)

59%

−0.95 [−2.18, 0.29]

0.13

0.18

Dose

 10 mg

6 (407)

12%

−0.32 [− 0.92, 0.28]

0.29

 

 20 mg

3 (206)

84%

−1.15 [−3.11, 0.81]

0.25

 

 40 mg

3 (159)

75%

0.67 [−1.18, 2.51]

0.84

 

 80 mg

2 (159)

0%

−0.35 [−1.42, 0.71]

0.52

0.62

Follow-up duration

 ≤ 8 weeks

8 (520)

0%

−0.19 [− 0.62, 0.24]

0.40

 

 > 8 weeks

6 (411)

82%

−0.59 [−2.20, 1.02]

0.47

0.64

Adiponectin assay

 ELISA

11 (720)

38%

−0.01 [− 0.57, 0.54]

0.96

 

 RIA

3 (211)

85%

−1.48 [−3.74, 0.79]

0.20

0.22

  1. Abbreviations: WMD weighed mean difference, CI confidence interval, R random, DB double-blinded, PC placebo-controlled, BMI body mass index, ELISA enzyme-linked immunosorbent assay, RIA radioimmunoassay
  2. 1p values for subgroup effects
  3. 2p values for subgroup interaction